Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small cell lung cancer

Lung Cancer

Volumn 20, Issue 2, 1998, Pages 99-108

  Mehdi, Syed A ^a,b   Etzell, Joan E ^c   Newman, Nancy B ^a,b   Weidner, Noel ^c   Kohman, Leslie J ^a,b   Graziano, Stephen L ^a,b  

^a SYRACUSE VA MEDICAL CENTER   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ki 67; Lung cancer; Ploidy; Prognosis; Proliferative marker; Symptoms

Indexed keywords

MONOCLONAL ANTIBODY KI 67; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; DISEASE COURSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SYMPTOM;

EID: 0032079577     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(98)00027-0     Document Type: Article

References (38)

1. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics, 1997. CA Cancer J Clin. 47:1997;5-27.
2. McDowell EM. Bronchogenic carcinomas. In: McDowell EM, editor. Lung Carcinomas. Edinburgh: Churchill Livingstone, 1987:255-285.
3. Carney D.N., Leij D. Lung cancer biology. Semin Oncol. 15:1988;199-214.
4. Vollmer R.T., Ogden L., Crissman J.D. Separation of small cell from non-small cell lung cancer. Arch Pathol Lab Med. 108:1984;792-794.
5. Minna JD, Sekido Y, Fong KM, Gazdar AF. Cancer of lung. In: Devita VT Jr, Hellman S, Rosenberg SA, editors. Cancer Principles and Practice of Oncology, 5th ed. Philadelphia: Lippincott, Raven, 1997, pp. 849-949.
6. The Lung and Cancer Study Group, Gail M.H., Eagan R.T., Feld R., Ginsberg R., Goodell B., Hill L., Holmes E.C., Wright P.W., Lake W.H. Prognostic factors in patients with resected stage I non-small cell lung cancer: a report from the lung cancer study group. Cancer (Phila). 54:1984;1802-1813.
7. Lipford E.H., Eaggleston J.C., Lillemoe K.D., Sears D.L., Moore G.W., Baker R.R. Prognostic factors in surgically resected limited stage NSCLC. Am J Surg Pathol. 8:1984;357-365.
8. Linnoila R.I., Ruckdeschel J.C., Piantadosi S., Jensen S.M., Mulshine J.L. The impact of neuroendocrine and epithelial differentiation on recurrence and survival in patients with resected NSCLC: the LCSG experience. Proc Am Soc Clin Oncol. 10:1991;248.
9. Graziano S.L., Tatum A.H., Newman N.B., Oler A., Kohman L.J., Veit L.J., Gamble G.P., Coleman M.J., Barmada S., Olear S. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II NSCLC. Cancer Res. 54:1994;2908-2913.
10. Isobe H., Miyamoto H., Shimizu T., Haneda H., Hashimoto M., Kawakami Y. Prognostic and therapeutic significance of flow cytometric nuclear DNA content in NSCLC. Cancer (Phila). 65:1990;1391-1395.
11. Zimmerman P.V., Bint M.H., Hawson G.A.T., Parsons P.G. Ploidy as a prognostic determinant in surgically treated lung cancer. Lancet. 8558:1987;530-533.
12. Slebos R.J.C., Kibbelaar R.E., Dalesio O., Kooistra A., Stam J., Meijer C.J.M., Wagennar S.S., Rodenhuis S. K-ras oncogene activation as a prognostic marker in adenocarcinoma of lung. N Engl J Med. 323:1990;561-565.
13. Harada M., Dosaka-Akita H., Miyamoto H., Kuzumaki N., Kawakami Y. Prognostic significance of expression of ras oncogene product in NSCLC. Cancer (Philadelphia). 69:1992;72-77.
14. Horio Y., Tamakawa K., Nakamura Y., Ueda R., Takahashi T. Prognostic significance of p53 mutations and 3p deletions in primary resected NSCLC. Cancer Res. 53:1993;1-4.
15. Kern J.A., Schwartz D.A., Nordberg J.E., Weiner D.B., Greene M.I., Torney L., Robinson R.A. p185 neu Expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 50:1990;5184-5191.
16. Pennzella F., Turley H., Kuzu I., Tungekar M.F., Dunnill M.S., Pierce C.B., Harris A., Gatter K.C., Mason D.Y. bcl-2 Protein in NSCLC. N Engl J Med. 329:1994;690-694.
17. Graziano S.L., Tatum A.H., Gonchoroff N.L., Newman N.B., Kohman L.J. Blood group antigen A and flow cytometric analysis in resected early stage non-small cell lung cancer. Clin Cancer Res. 3:1997;87-93.
18. Lee J.S., Ro J.Y., Sahin A.A.et al. Expression of blood-group antigen-A: a favorable prognostic factor in non-small cell lung cancer. N Engl J Med. 324:1991;1084-1090.
19. Fontanini G., Lucchi M., Vignati S., Mussi K., Ciardiello F., De Laurentis M., De Placido S., Basolo F., Angeletti C.A., Bevilacqua G. Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma. J Natl Cancer Inst. 89(12):1997;881-886.
20. Tubiana M., Courdi A. Cell proliferation kinetics in human solid tumors: relation to probability of metastatic dissemination and long-term survival. Radiother Oncol. 15:1989;1-18.
21. Gerdes J., Schwab U., Lemke H., Stein H. Production of a mouse monoclonal antibody reactive with human nuclear antigen associated with cell proliferation. J Cancer. 31:1983;13-20.
22. Pence J.C., Kerns B.M., Dodge K.D., Iglehart D. Prognostic significance of the proliferation index in surgically resected non-small cell lung cancer. Arch Surg. 128:1993;1382-1390.
23. Scagliotti G.V., Micela M., Gubetta L., Leonardo E., Cappia S., Borasio P., Pozzi E. Prognostic significance of Ki-67 labeling in resected NSCLC. Eur J Cancer. 29A:1993;363-365.
24. Tungekar M.F., Gatter K.C., Dunnill M.S., Mason D.Y. Ki-67 immunostaining and survival in operable lung cancer. Histopathology. 19:1991;545-550.
25. Simony J., Purjol J.L., Radal M., Ursule E., Michel F.B. In situ evaluation of growth fraction determined by monoclonal antibody Ki-67 and ploidy in surgically resected NSCLC. Cancer Res. 50:1990;4382-4387.
26. Harpole D.H., Herndon J.E., Wolfe W.G., Iglehart J.D., Marks J.R. A prognostic model of recurrence and death in stage I NSCLC utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 55:1995;51-56.
27. Stanley K.E. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 65:1980;25-32.
28. Paesmans M., Sculier J.P., Libert P., Bureau G., Dabouis G., Thiriaux J., Michel J., Van Cutsem O., Sergysels R., Mommen P., Klatersky J. Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. J Clin Oncol. 13:1995;1221-1230.
29. Sorensen J.B., Badsber J.H. Prognostic factors in resected stage I and II adenocarcinoma of the lung. J Thorac Cardiovasc Surg. 99:1990;218-226.
30. Mountain C.F. Prognostic implications of the international staging system for lung cancer. Semin Oncol. 15:1988;236-245.
31. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 53:1985;457-481.
32. Lee ET. Statistical Models for Survival Data Analysis. Belmont, CA: Life Time Learning Publications, 1980.
33. SAS Institute. Procedure for Proportional Hazard Regression, version 6.09. Cary, NC: SAS Institute, 1988.
34. Cox DR, Oakes D. Analysis of Survival Data. London: Chapman and Hall, 1984.
35. Graziano S.L. Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer. 17(Suppl 1):1997;S37-58.
36. Strauss G.M. Prognostic markers in resectable non-small cell lung cancer. Hematol Oncol Clin North Am. 11(3):1997;409-433.
37. Soomro IN, Baker GM, Littleton RJ, Whimster WF. Ki-67 positivity and prognosis in lung cancer. J Pathol 1991;163:A157.
38. Orntoft T.F., Wolf H., Clausen H., Dabelsteen E., Hakomori S.I. Blood group ANH-related antigens in normal and malignant bladder urothelium: possible structural basis for the deletion of type-2 chain ABH antigens in invasive carcinomas. Int J Cancer. 43:1989;774-780.